2024年度

I. 学会発表

1. 勝山修行, 廣渡祐史, 由雄祥代, 箱島真理子, 足立洋希, 柳内秀勝. 高度肥満患者における減量手術前後のリポ蛋白プロファイルの変化. 第67回日本糖尿病学会年次学術集会. 2024/5/17-19, 東京.
2. 堀中誠一, 勝山修行, 箱島真理子, 足立洋希, 柳内秀勝. 2型糖尿病患者における非アルコール性脂肪性肝疾患の進展に対するSGLT2阻害薬の長期的影響に関する後ろ向き観察研究. 第67回日本糖尿病学会年次学術集会. 2024/5/17-19, 東京.
3. 雨宮笑歌, 勝山修行, 箱島真理子, 足立洋希, 柳内秀勝. 日本人2型糖尿病患者におけるGLP-1受容体作動薬セマグルチド注射薬の非アルコール性脂肪性肝疾患の進展への影響. 第67回日本糖尿病学会年次学術集会. 2024/5/17-19, 東京.
4. 堀中萌, 箱島真理子, 足立洋希, 増井良則, 勝山修行, 柳内秀勝. 高齢者における血糖コントロールと誤嚥性肺炎の転帰との関連についての後ろ向き観察研究. 第67回日本糖尿病学会年次学術集会. 2024/5/17-19, 東京.
5. 箱島真理子, 勝山修行, 柳内秀勝. 頸動脈超音波検査の糖尿病との関連についての後ろ向き観察研究. 第67回日本糖尿病学会年次学術集会. 2024/5/17-19, 東京.
6. 雨宮笑歌, 梅山翔平, 西嶋碧乃, 狩野俊和, 箱島真理子, 足立洋希, 勝山修行, 柳内秀勝. 中枢性尿崩症、冠動脈炎を呈したIgG4関連疾患の1例. 第34回臨床内分泌代謝 2024/11/29-30, 名古屋.
7. 勝山修行, 箱島真理子, 足立洋希, 柳内秀勝. 2型糖尿病における持続性GLP-1受容体作動薬セマグルチドの多面的代謝改善作用に関する後ろ向き観察研究. 第121回日本内科学会総会・講演会. 2024/4/12-14, 東京.
8. 飯田さくら, 箱島真理子, 勝山修行, 柳内秀勝. 甲状腺性疾患における精神疾患の合併の状況と精神症状との関連についての後ろ向き観察研究. 第97回日本内分泌学会学術総会. 2024/6/6-8, 横浜.
9. Hisayuki Katsuyama, Mariko Hakoshima, Hidekatsu Yanai. Temporal trends and contemporary use of insulin pump therapy for patients with type 1 diabetes in Japan. 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025). 19-22 March, 2025, Amsterdam, The Netherlands.
10. Mariko Hakoshima, Sarina Tanida, Hisayuki Katsuyama, Naoko Satake, Hidekatsu Yanai. The associations between thyroid hormone state and psychiatric symptoms in hospitalized patients with bipolar disorder or depression. American Thyroid Association (ATA) 2024 Annual Meeting. 30 October-3 November, 2024, Chicago, US.
11. Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama. Effects of a novel uricosuric drug, the selective urate 1 inhibitor, dotinurad, on metabolic parameters. 92th European Atherosclerosis Society (EAS) Congress. 26-29 May, 2024, Lyon, France.
12. Hisayuki Katsuyama, Yuji Hirowatari, Dausike Manita, Mariko Hakoshima, Takumi Kawaguchi, Sachiyo Yoshio, Susumu Inamine, Hidekatsu Yanai. Changes in lipid profile during 12 months after sleeve gastrectomy in Japanese patients with severe obesity. 92th European Atherosclerosis Society (EAS) Congress. 26-29 May, 2024, Lyon, France.

II. 論文

1. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Pathology and Treatments of Alzheimer's Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes. Molecules. 2024;29(24):5936.
2. Katsuyama H, Horinaka S, Hakoshima M, Adachi H, Yanai H. Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients. J Clin Med. 2024;13(16):4929.
3. Yanai H, Adachi H, Hakoshima M, Katsuyama H, Sako A. The Significance of Endothelial Dysfunction in Long COVID-19 for the Possible Future Pandemic of Chronic Kidney Disease and Cardiovascular Disease. Biomolecules. 2024;14(8):965.
4. Katsuyama H, Hakoshima M, Heshiki T, Iida S, Adachi H, Yanai H. Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan. Diabetes Res Clin Pract. 2024;213:111752.
5. Katsuyama H, Hakoshima M, Kaji E, Mino M, Kakazu E, Iida S, Adachi H, Kanto T, Yanai H. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data. Biomedicines. 2024;12(5):1001.
6. Yanai H. Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes. J Med Cases. 2024;15(2-3):37-42.
7. Kawasaki E, Awata T, Ikegami H, Imagawa A, Oikawa Y, Osawa H, Katsuki T, Kanatsuna N, Kawamura R, Kozawa J, Kodani N, Kobayashi T, Shimada A, Shimoda M, Takahashi K, Chujo D, Tsujimoto T, Tsuchiya K, Terakawa A, Terasaki J, Nagasawa K, Noso S, Fukui T, Horie I, Yasuda K, Yasuda H, Yanai H, Hanafusa T, Kajio H; Japanese Type 1 Diabetes Database Study (TIDE‐J). Prediction of future insulin-deficiency in glutamic acid decarboxylase autoantibody enzyme-linked immunosorbent assay-positive patients with slowly-progressive type 1 diabetes. J Diabetes Investig. 2024;15(7):835-842.
8. Shoji T, Kogure K, Toda N, Hakoshima M, Katsuyama H, Yanai H, Tokunaga S, Tateoka K, Tsuji T, Okura T. Association between comorbidities associated with diabetes and higher-level functional status in older patients with type 2 diabetes mellitus: a cross sectional study. Eur Geriatr Med. 2024;15(4):1101-1110.
9. Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb. 2024;31(6):641-853. d
10. Yanai H. A Significant Effect of Pemafibrate on Carotid and Cerebral Atherosclerosis in Patients with Hypertriglyceridemia and Stroke. J Atheroscler Thromb. 2025.
11. Yanai H, Yoshinobu M, Adachi H. A Significance of Selective Inhibition of Urate Transporter 1 and Non-Inhibition of Adenosine Triphosphate-Binding Cassette Transporter in Renal Function in a Patient With Advanced Stage Chronic Kidney Disease. Journal of Endocrinology and Metabolism. 2024;14(2): 85-88.
12. Sako A, Yada T, Fujiya K, Nakashima R, Yoshimura K, Yanai H, Uemura N. Clinical epidemiology of the endoscopic, laparoscopic, and surgical resection of malignant gastric tumors in Japan, 2014-2021: a retrospective study using open data from a national claims database. Gastric Cancer. 202;28(1):1-11.